Fig. 6.

TRAIL shows a synergistic effect in combination with the BCL-2 inhibitor venetoclax in the presence of TP53INP2 in vitro. a The schematic depiction of experiments about drug treatment. b-c CCK-8 analysis (n = 3) of cell viability in the OCI-AML3 cells (b) and primary blasts (c) treated with TRAIL and VEN, alone or incombination for 48 h. SynergyFinder was used to evaluate the ZIP synergy score. d Colony formation assay was performed in the OCI-AML3 and AML#3 cells (Scale bar: 50 μm). The representative images and quantitative data from three independent experiments were shown in (d, left) and (d, right), respectively. e FCM analysis (e, left) and quantification (e, right) of apoptotic cells in the OCI-AML3 and AML#3 cells treated with TRAIL and VEN, alone or in combination for 48 h. f-g Quantification of apoptotic cells by FCM (n = 3) in the AML#5 cells (f) and AML#6 cells (g) treated with TRAIL and VEN, alone or in combination for 48 h. h-i CCK-8 assay (n = 3) of cell viability (h) and quantification of apoptotic cells (i) in the mononuclear cells from healthy donors. The cells incubated in a drug-free medium served as controls. The data are representative of at least three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, not significant